Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer

Systemic treatment for triple negative breast cancer (TNBC: negative for the expression of estrogen receptor and progesterone receptor and HER2 amplification) has been limited to chemotherapy options. Neoadjuvant chemotherapy induces tumor shrinkage and improves the surgical outcomes of patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ademuyiwa, Foluso O., Ellis, Matthew J., Ma, Cynthia X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747378/
https://www.ncbi.nlm.nih.gov/pubmed/23983689
http://dx.doi.org/10.1155/2013/219869